Current Report Filing (8-k)
May 14 2020 - 12:00PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
|
Date of Report: May 14, 2020
(Date of earliest event reported)
|
ImmuCell
Corporation
(Exact name of registrant as specified in its charter)
|
|
DE
(State or other jurisdiction
of incorporation)
|
001-12934
(Commission File Number)
|
01-0382980
(IRS Employer
Identification Number)
|
|
56
Evergreen Drive
Portland,
Maine
(Address of principal executive offices)
|
|
04103
(Zip Code)
|
207-878-2770
(Registrant's telephone number, including area code)
|
|
Not
Applicable
(Former Name or Former Address, if changed since last report)
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant
under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act: None
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item
8.01. Other Events
On
May 14, 2020 ImmuCell Corporation (the “Company”) issued a press release announcing that it will hold its Annual Meeting
of Stockholders by remote communication in the form of both a dial-in conference call and an audio webcast rather than an in-person
event on Wednesday, June 10, 2020 at 3:00 PM ET. The full text of the press release issued in connection with the announcement
is attached as Exhibit 99.1 to this Current Report on Form 8-K.
The
information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange
Act") or otherwise subject to liabilities of that section, nor shall it be deemed incorporated by reference in any filing
under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits.
The
following exhibit relating to Item 8.01 shall be deemed to be furnished, and not filed:
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
IMMUCELL CORPORATION
|
|
|
|
|
Date: May 14, 2020
|
By:
|
/s/ Michael
F. Brigham
|
|
|
Michael F. Brigham
|
|
|
President, Chief Executive Officer and Principal Financial Officer
|
Exhibit
Index
ImmuCell (NASDAQ:ICCC)
Historical Stock Chart
From Mar 2024 to Apr 2024
ImmuCell (NASDAQ:ICCC)
Historical Stock Chart
From Apr 2023 to Apr 2024